CAMP4 Therapeutics Corp
NASDAQ:CAMP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CAMP4 Therapeutics Corp
NASDAQ:CAMP
|
US |
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
US |
|
Kelsian Group Ltd
ASX:KLS
|
AU |
|
EnBW Energie Baden Wuerttemberg AG
XETRA:EBK
|
DE |
|
Universal Health Services Inc
NYSE:UHS
|
US |
|
D
|
Dong Phu Rubber JSC
VN:DPR
|
VN |
|
CIMIC Group Ltd
ASX:CIM
|
AU |
|
Risanamento SpA
MIL:RN
|
IT |
|
W
|
Woolworths Group Ltd
OTC:WOLWF
|
AU |
|
Newegg Commerce Inc
NASDAQ:NEGG
|
US |
|
V
|
VMware Inc
XETRA:BZF1
|
US |
|
Goal Acquisitions Corp
OTC:PUCK
|
US |
|
S
|
Shandong Weida Machinery Co Ltd
SZSE:002026
|
CN |
|
AES Brasil Energia SA
BOVESPA:AESB3
|
BR |
CAMP4 Therapeutics Corp
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2024-10-11. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2024-10-11. The company is leveraging its RAP Platform to advance a pipeline of programs initially focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
